<DOC>
	<DOCNO>NCT01605305</DOCNO>
	<brief_summary>The aim study explore whether FOLFOX6 treatment could improve time progression ( TTP ) overall survival ( OS ) patient recurrent metastatic esophagus .</brief_summary>
	<brief_title>Study FOLFOX6 First-line Therapy Treat Recurrent Metastatic Esophageal Cancer</brief_title>
	<detailed_description>Explore whether FOLFOX6 treatment could improve TTP OS patient recurrent metastatic esophagus</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Histologically proven primary thoracic esophageal squamous cell carcinoma 2 . Without chemotherapy neoadjuvant chemotherapy 6 week , radiotherapy end least 1 month , target lesion irradiated area . 3 . Presence least one index lesion measurable CT scan MRI 4 . 18~75 year 5. kps ≥ 70 6 . Life expectancy ≥ 3 month 7 . ANC ≥ 2×109/L，PLT ≥ 100×109/L，Hb ≥ 90g/L 8 . Cr ≤ 1.0×UNL 9 . TB ≤ 1.25×UNL； ALT/AST ≤ 2.5×UNL，THE patient liver metastasis ALT/AST ≤ 5.0×UNL；AKP ≤ 2.5×UNL 10 . Signed write informed consent 1 . Previous exposure oxa therapy one year 2. diameter tumor abdominal ≥ 10cm , Total volumes liver lesion ≥ 50 % , lung metastasis ≥ 25 % total lung 3. chronic diarrhea , enteritis , intestine obstruction control 4 . Psychiatric addictive disorder preclude obtain inform consent adherence protocol . 5. peripheral neuropathy ≥ CTCAE 1 6 . Other serious disease 7 . Previous concomitant malignancy except nonmelanoma skin cancer , carcinoma situ cervix , invasive carcinoma colon , thyroid , cervix , endometrium treat five year prior study entry . 8 . USE OTHER ANTITUMOR THERAPY 9 . Breastfeeding pregnant woman , effective contraception risk conception exists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>